Glaucoma drug helps restore vision loss linked to obesity

by Jim Dryden
Glaucoma drug helps restore vision loss linked to obesity
Working with colleagues at 38 centers nationwide, Washington University neuro-ophthalmologist Gregory P. Van Stavern, MD, has found that combining a glaucoma drug with a weight-loss program can improve vision in patients with the disorder known as idiopathic intracranial hypertension. Credit: Robert Boston

(Medical Xpress)—A new study shows that the eyesight of patients with an unusual vision disorder linked to obesity improves twice as much if they take a glaucoma drug and lose a modest amount of weight than if they only lose weight.

The condition, called idiopathic intracranial hypertension, affects an estimated 100,000 people in the United States. Most are obese women ages 20 to 50.

The researchers recently reported their results in The Journal of the American Medical Association.

The condition's most common symptoms are headaches and vision problems, including blind spots, poor peripheral vision, double vision and temporary episodes of blindness. Five to 10 percent of women with the disorder experience disabling vision loss. Only about 5 percent of cases involve men.

"The condition results in elevated pressure in the fluid surrounding the brain and the spinal cord," said co-author Gregory P. Van Stavern, MD, a neuro-ophthalmologist at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis. "We don't completely understand the disorder but know it affects the optic nerve because when fluid pressure is elevated, the optic nerve is swollen when we examine the eye."

Previous research has found that losing 5 to 10 percent of body weight can improve symptoms in many patients. The glaucoma drug used in the study, acetazolamide, is a diuretic given to glaucoma patients to reduce pressure in the eye. Many eye specialists also have prescribed the drug—given as a pill rather than eye drops—to reduce fluid production in and around the brain.

The disorder also is called pseudotumor cerebri because its symptoms resemble those of a brain tumor, and it is becoming more common as the obesity epidemic grows. In developing countries where obesity is uncommon, very few cases of idiopathic intracranial hypertension exist, Van Stavern said.

The study was conducted at 38 clinical sites in the United States and included 161 women and four men with the disorder and mild vision loss.

At the time subjects enrolled in the study, their average body mass index (BMI) was about 40. A BMI of 30 or greater is considered obese.

Participants were placed on an exercise plan and diet designed to lower salt intake and cut 500 to 1,000 calories each day. The goal was to get subjects to lose at least 6 percent of their body weight. In addition to dietary advice, all study subjects were provided with a weight-loss coach and low-cost exercise equipment.

About half of the participants also randomly were chosen to receive acetazolamide. When the study began, subjects received 1 gram of the drug per day. The dose then was increased by a quarter of a gram each week until study patients reached their maximum tolerated dose or were taking up to 4 grams of the drug daily. The other participants received an inactive placebo with escalating "dosages" during the study.

"Acetazolamide makes certain foods and carbonated beverages taste really bad," said Van Stavern, an associate professor of ophthalmology and visual sciences and of neurology. "Some experts thought that acetazolamide might be causing people to lose weight just because they avoided foods that didn't taste good."

But the researchers found an additional benefit in participants taking the drug. After six months, patients in both study groups had improved vision. But for those who lost weight and took the drug, eyesight improved almost twice as much as in those who lost weight but got the placebo.

At the end of the study, those who took the glaucoma drug also had less swelling in the than those who lost weight and received the placebo. The drug-weight loss combination also was linked to greater improvements in daily function and quality of life.

"So although both groups did well, the patients who took the drug and did the weight-loss regimen fared much, much better," Van Stavern explained. "Their vision improvement was independent of the fact that the drug makes some foods taste lousy."

Van Stavern said he expects more information will be culled from the data over the next few years. Several hormones and a number of genes have been linked to idiopathic intracranial hypertension, and those factors are being analyzed. But for now, the researchers said many patients stand to benefit.

"This study provides a much-needed evidence base for using acetazolamide as an adjunct to weight loss," said Michael Wall, MD, the national director of the study and a professor of neurology and ophthalmology at the University of Iowa in Iowa City. "This has been around since the 1950s, and prior studies have found varying degrees of efficacy. One strength of our study is that we slowly introduced patients to the highest tolerated dose in an attempt to maximize efficacy while limiting side effects."

More information: Wall M, et al for the NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, "Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial." The Journal of the American Medical Association, vol. 311 (16), pp. 1641-1651. April 23/30, 2014. DOI: 10.1001/jama.2014.3312

Related Stories

Recommended for you

Detecting eye diseases using smartphone technology

date 3 hours ago

Researchers at the Medical and Surgical Center for Retina have developed software that detects eye diseases such as diabetic macular edema using a smartphone. The system is aimed at general physicians who ...

Miniature pump regulates internal ocular pressure

date Jul 01, 2015

Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing ...

Closing the Australian eye health gap may be in sight

date Jun 30, 2015

Three years after the launch of the roadmap to close the gap for vision, progress has been made but "much remains to be done", according to the authors of a Perspective published online today by the Medical Jo ...

Pioneering gene therapy takes aim at inherited blindness

date Jun 29, 2015

Canada's first human gene therapy trial for eyes—the replacement of a faulty gene with a healthy one—is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people ...

Iris research focuses on blood vessel patterns

date Jun 29, 2015

The structure of the microvasculature or blood vessels in the iris could play an important role in people's contraction of eye maladies like glaucoma and cataract, according to a WA-led study.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Jun 26, 2014
This drug seems to be very beneficial. I was unaware until recently that obesity could have an effect on vision.

The ability to get rid of unnecessary fat in particular is something that could help regarding diabetes and obesity for example. I am saying this based on my understanding of what I have read concerning the link between weight loss and these conditions.

A video I have watched the first time not extremely long ago gave me information that I was not necessarily expecting about weight loss. There is a link to it on this page:

However, I don't believe in depriving oneself completely from delicious, tasty and lawful food just to follow a particular diet. If it can be followed over the long term, does it truly help?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.